BRD4 and prostate carcinoma: The subgroup of BET proteins (bromodomain and extra-terminal), and in particular BRD4, have been the best characterized in prostate cancer, and several inhibitors of BET bromodomains have been developed and are currently in clinical trial (see Table 2).